HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIR Affirms Triclosan Safety, Opts For Formaldehyde Re-Review

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel tackled a number of controversial issues at its Dec. 13-14 meeting in Washington.

You may also be interested in...



CIR Proposes Prioritizing Triclosan For Review In 2018

The Cosmetic Ingredient Review Expert Panel’s draft ingredient priority list for 2018 review consists of 14 ingredients, including triclosan. At their April meeting, panelists cited the potential for consumer confusion following recent FDA action banning the ingredient’s OTC use in antibacterial soaps, as well as endocrine-disruption concerns voiced by NGOs.

CIR To Reconsider Retinol, Triclosan, Parabens In Light Of New Data

The Cosmetic Ingredient Review Expert Panel will entertain new data regarding the safety of retinol/retinyl palmitate, triclosan and parabens at its next meeting to determine if safety assessments for the ingredients should be re-opened for further review.

Researchers Call For Reduced Triclosan Use Following NIH-Funded Study

Industry has come out against a study exploring the impact of triclosan on cardiac and skeletal muscle function in animals, which they say is a “publicity campaign” and used “unrealistically large” doses of the anti-bacterial ingredient that do not represent real-world conditions. The NIH-funded study prompted investigators to call for a “dramatic reduction” in the ingredient’s use in consumer products.

Related Content

UsernamePublicRestriction

Register

RS017363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel